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Trajectory: [RC] [P1] [P2] [DU] [RCS]
Total Time (ns): 102.6 65.0 83.6 80.0 145.0
Events (ns):
S∗ 37.1 45.9 27.0 12.6 34.0
R∗(4,8) 35.2 46.6 21.4 9.6 30.8
R∗(2,8) 7.6 8.1 5.9 0.4 19.0
R∗(3,8) 5.9 14.7 1.7 1.7 18.0
Table 1: Table of total accumulated times of events in each of the five trajectories.
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Overlaps: S∗
⋂
R∗(4,8) R∗(4,8)
⋂
SB R∗(4,8)
⋂
R∗g R
∗(2,8)
⋂
R∗(3,8)
S∗ R∗(4,8) R∗(4,8) SB R∗(4,8) R∗g R
∗(2,8) R∗(3,8)
Trajectory:
[RC] 91.9 96.7 34.9 90.8 72.3 79.7 0.0 0.0
[P1] 97.1 95.6 40.6 84.9 95.9 85.8 5.3 2.9
[P2] 76.0 95.8 1.2 3.4 73.9 45.7 0.0 0.0
[DU] 72.6 95.7 4.3 19.7 68.1 41.3 5.7 1.4
[RCS] 85.7 94.6 54.1 70.4 81.1 60.2 70.1 73.9
Table 2: Table of percentage of overlap (columns) between pairs of events per trajectory
(rows).
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Abstract
Experimental evidence suggests that the folding and aggregation of the amyloid
β-protein (Aβ) into oligomers is a key pathogenetic event in Alzheimer’s disease (AD).
Inhibiting the pathologic folding and oligomerization of Aβ could be effective in the
prevention and treatment of AD. Here, using all-atom molecular dynamics simulations
in explicit solvent, we probe the initial stages of folding of a decapeptide segment of Aβ,
Aβ21−30, shown experimentally to nucleate the folding process. In addition, we examine
the folding of a homologous decapeptide containing an amino acid substitution linked
to hereditary cerebral hemorrhage with amyloidosis–Dutch type, [Gln22]Aβ21−30 . We
find that: (i) when the decapeptide is in water, hydrophobic interactions and transient
salt bridges between Lys28 and either Glu22 or Asp23 are important in the formation
of a loop in the Val24–Lys28 region of the wild type decapeptide; (ii) in the presence
of salt ions, salt bridges play a more prominent role in the stabilization of the loop;
(iii) in water with a reduced density, the decapeptide forms a helix, indicating the
sensitivity of folding to different aqueous environments; (iv) the “Dutch” peptide in
water, in contrast to the wild type peptide, fails to form a long-lived Val24–Lys28
loop, suggesting that loop stability is a critical factor in determining whether Aβ folds
into pathologic structures. Our results are relevant to understand the mechanism of Aβ
peptide folding in different environments, such as intra- and extracellular milieus or cell
membranes, and how amino acid substitutions linked to familial forms of amyloidosis
cause disease.
Keywords: molecular dynamics, amyloid β-protein, Alzheimer’s disease, nucleation,
protein folding.
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1 Introduction
The amyloid cascade hypothesis, first proposed in the early 1990’s, posits that the deposition
of amyloid fibrils is the seminal event in the pathogenesis of Alzheimer’s disease (AD) [1, 2].
However, recent biophysical, biological, and clinical data indicate that the formation of
oligomeric assemblies much smaller than fibrils may be a key pathologic event [3–10]. This
paradigm shift suggests an attractive therapeutic approach–prevent or disrupt the assembly
of Aβ monomer into toxic oligomers. To do so requires an understanding of the molecular
dynamics involved in the transition from non-toxic monomeric to toxic oligomeric states.
Elucidation of the initial events in Aβ monomer folding and assembly is complicated
by the solvent dependence of the process [11]. Monomeric Aβ is largely helical in a mem-
brane or membrane-mimicking environment such as ionic detergents [12–15]. In contrast, Aβ
monomers in aqueous solution show negligible α-helix or β-sheet content [11, 16, 17]. Stud-
ies of Aβ10−35-amide at micromolar concentrations in water show a pH-dependent folding
transition in which the conformation is not helical but contains several turns and at least
two short strands [18]. Solution-state NMR combined with diffusion-ordered spectroscopy
indicate that variation of the anionic strength in the buffer shifts the equilibrium between
monomeric and oligomeric states, possibly allowing for the stabilization of intermediate struc-
tures [19]. Molecular dynamics (MD) studies of Aβ16−22 monomer in aqueous urea solution
show that increasing the concentration of urea promotes a transition from a compact random
coil to β-strand structures [20].
Aβ folding and oligomerization are also influenced significantly by amino acid structure
at specific sites. The dipeptide Ile41-Ala42 at the C-terminus of Aβ1−42 is responsible for the
different biophysical behaviors of Aβ1−42 and Aβ1−40 [21, 22]. Oxidation of Met35 disrupts
2
Aβ1−42 oligomer formation but does not affect Aβ1−40 oligomer formation, consistent with
the possibility that there are structural differences between oligomers of the two alloforms
involving Met35 and neighboring residues [23]. Simulations of the oligomerization of Aβ1−40
and Aβ1−42 [24, 25] using discrete MD (DMD) with implicit solvent [26–29] are consistent
with in vitro data, yield new structural predictions, and offer a plausible mechanistic ex-
planation of the Met35 oxidation experiments [25]. MD studies show that the presence of
glycines induce a transition from an α-helix to a β-strand conformation in Aβ1−40 monomers
in aqueous solution [30]. Simulation studies of the Dutch [Gln22]Aβ10−35 peptide in water
indicate that interactions between the peptide and the solvent are stronger in the wild type
than in the mutant peptide [31].
Recent limited proteolysis experiments on Aβ1−40 and Aβ1−42, under conditions favoring
oligomerization, identify in both peptides a protease-resistant segment, Ala21–Ala30. The
homologous decapeptide Aβ21−30 shows identical protease resistance [32]. Structure calcu-
lations based on distance constraints from proton solution-state NMR of Aβ21−30 reveal a
turn structure at Val24–Lys28. Lazo et al. [32] postulate that this structure nucleates the
intramolecular folding of the Aβ monomer and that partial unfolding of the Ala21-Ala30
region may be necessary for the subsequent fibrillization of Aβ. The observations on full-
length Aβ and on the Aβ21−30 decapeptide are consistent with previous work showing that
peptide fragments containing the folding nuclei of globular proteins are, by themselves, struc-
tured [33]. Furthermore, the structures found in the isolated folding nuclei are similar to
those found in the full-length proteins [33]. MD simulations of the folding nucleus, therefore,
provide insights into the earliest events in the folding of the full-length protein. Borreguero
et al. recently used DMD with implicit solvent and a united-atom protein model to simulate
folding of the putative Aβ folding nucleus Aβ21−30 [34]. The united-atom peptide model
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considers explicitly all protein atoms except hydrogen. Important findings in Borreguero
et al. [34] are: (i) the existence of a loop that is stabilized by hydrophobic interactions in
the Val24–Lys28 region; (ii) a high degree of flexibility in the termini; and (iii) electrostatic
interactions between the charged groups of Glu22, Asp23, and Lys28 that modulate the
stability of the folded structure.
Here we test whether the stability of the Val24–Lys28 loop described by Borreguero et
al. [34] persists in simulations that consider an explicit solvent (all atoms are included in
the simulation). In addition, we determine the effects of solvent alterations on the folding
dynamics and investigate the changes in the dynamics caused by amino acid substitutions.
To this end, we present results of long-time, all-atom MD simulations of Aβ21−30 in explicit
water. We also study the dynamics of the monomer containing the Dutch [Gln22]Aβ21−30
mutation. This mutation leads to hereditary cerebral hemorrhage with amyloidosis–Dutch
type (HCHWA-D), characterized by extensive deposition of Aβ1−40 in arterioles and small
cerebral vessels but only limited senile plaque formation. In vitro studies indicate that the
Dutch Aβ has a greater tendency to form protofibrils and fibrils than does the wild type Aβ
[3, 35]. To investigate dynamical differences in the folding due to changes in the composition
and density of the solvent, we study the system with solvated ions in normal density water
and in water with a reduced density. Our results are consistent with previous results [34]
and, in addition, reveal a helix conformation of the decapeptide when the encompassing
water has a lower density than normal water. Simulations with solvated ionic atoms in the
water illustrate how a different solvent composition can influence the role of salt bridges
between the charged amino acids by strengthening the stability of the Val24–Lys28 loop. In
addition, simulations of Aβ21−30 containing the Dutch [Gln22]Aβ21−30 mutation suggest that
the experimentally-observed increased fibril formation of this peptide may be a consequence
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of the increased number of aggregation-prone unpacked conformations.
2 Methods
MD Simulations. We perform long-time MD simulations of Aβ21−30 monomer in water at
normal and reduced density, normal density water with dissociated salt ions, and the Dutch
[Gln22]Aβ21−30 monomer in normal density water. We explicitly consider all atoms with
potential energies given by the CHARMM-27 force-field [36] using the NAMD package [37].
We use the TIP3P [38] model for the water molecules. We use the NVT ensemble and confine
the system in a box with periodic boundary conditions. We carry out the MD simulations
at a constant temperature of T = 283K, corresponding to the in vitro experiments [32].
Aβ21−30 has the primary structure Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala, where Glu22
and Asp23 are negatively charged and Lys28 is positively charged, while the Dutch muta-
tion [39] substitutes Glu22 by Gln22 (neutral). Following [32], we block Aβ21−30 with NH
+
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and CO−2 at the N- and C- termini, respectively. We generate five trajectories with the
following initial conditions:
• [RC], wild type random coil conformation in normal density water;
• [P1] & [P2], wild type loop conformations from Lazo et al. [32] in water with reduced
density (corresponding to Families I and II from Ref. [32], respectively);
• [DU], Dutch peptide in a random coil conformation in normal density water;
• and [RCS], wild type random coil conformation in salted water.
We choose these five trajectories because they give information about the dynamics of the
wild type Aβ21−30 in normal water and water with a reduced density, starting from ex-
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perimentally postulated conformations ([P1] and [P2]) and a control [RC]. These are then
compared with the Dutch [DU] and with the wild type peptide in a salted solvent [RCS].
We solvate each monomer by inserting it in the center of a previously-equilibrated cube
of water molecules of side 43A˚. This insertion deletes all water molecules overlapping or in
close proximity (<2.4A˚) to any of the monomer atoms, resulting in a system with about 2542
water molecules (see Supporting Information for details). To maintain system neutrality (for
wild type only), we insert a single Na+ ion far from the monomer. To obtain the “salted”
system, we insert 25 dissociated molecules of NaCl, resulting in a system with 2399 water
molecules. We carry out all the insertions and preparations of the systems using the VMD
package [40]. We use the Particle Mesh Ewald method [41] to calculate the electrostatic
interactions and a cut-off distance of 12A˚ for the direct electrostatic and van der Waals
interactions. We use a timestep of 1 fs for all simulations and save configurations (monomer
and water) every 2 ps.
We first minimize the energy of the system for 20,000 steps by applying the conjugate
gradient algorithm that relaxes all atoms except the Cα atoms. Next, we release the Cα
atoms and minimize again for another 20,000 steps. Then, we gradually heat the system in
the NVT ensemble from 0 to 283K by harmonically constraining all Cα atoms for 100 ps.
Following this step, and still constraining the Cα atoms, we then perform another 200 ps in
the NPT ensemble at 283K, followed by a brief 50 ps NPT simulation with no constraints
to generate the starting configuration for the production runs. Because of the way that
we delete overlapping water molecules in the solvation step above, these NPT equilibration
steps allow for water molecules to fill in holes left from the insertion of the decapeptide, thus
shrinking the size of the system by about 1A˚ in all directions (see Supporting Information
for details). For trajectories [P1] and [P2], we skip the NPT equilibration, not allowing
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the system to shrink, thus creating a system in which the effective density of the water is
reduced by about 7.5%. In Table 3 (Supporting Information) we list all of the thermodynamic
quantities for each of the trajectories. Total simulation times for the production runs are
102.6 ns for [RC], 65 ns for [P1], 83.6 ns for [P2], 80.0 ns for [DU], and 145.0 ns for [RCS].
Although these simulation times are too small to study the totality of the folding process of
the Aβ21−30, they are long enough to exhibit characteristic elements of the dynamics of the
folding for this decapeptide.
Structural Determinants. One of the most important quantities characterizing the
structure of Aβ21−30 is the distance between atoms. The notation R(x, y) signifies the dis-
tance R between two specified atoms from amino acid x and amino acid y. The quantities
we use to characterize the structure of Aβ21−30 as a function of simulation time are: (i) the
distance between the two Cα atoms of Ala21 and Ala30 (denoted by R(1,10)) and Val24
and Lys28 (denoted by R(4,8)); the distance between Lys28(Nζ) and Glu22(Cδ) (denoted by
R(2,8)); the distance between Lys28(Nζ) and Asp23(Cγ) (denoted by R(3,8)), (ii) the radius
of gyration Rg of the monomer given by R
2
g ≡
∑
imi(|
−→ri − −→rc |)
2/
∑
imi, where
−→rc is the
center of mass, (iii) the combined solvent accessible surface area (SASA) [42] of the Val24
and Lys28 side chains (denoted by S), (iv) the hydrogen bond contact maps between amino
acids, (v) the secondary structure propensity for each amino acid, (vi) the normalized scalar
product D between the vector joining Cα and Cβ of Val24 and the vector joining Cα and Cǫ
of Lys28, and (vii) the number and type of hydrogen bonds (HB) between atoms in the de-
capeptide [40]. We calculate secondary structure propensity using the program STRIDE [43]
available through the VMD package. A HB exists if the distance between donor and acceptor
is ≤3A˚ and the angle θ between the donor–hydrogen–acceptor atoms is 160◦ ≥ θ ≤ 200◦.
If, in addition, two hydrogen-bonded atoms are of opposite charge, they form a salt bridge
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(SB) [44].
The quantities defined above provide a broad qualitative and quantitative description of
the structure of Aβ21−30. In particular, the distance R(4,8) monitors possible formation of a
loop involving the Val24–Lys28 region and close proximity of the hydrophobic parts of the
Val24 and Lys28 side chains. The secondary structure propensity per amino acid determines
general structure. A decrease of the combined SASA of two side chains indicates that
the side chains are packed, reducing their contact with the solvent. A reduced normalized
scalar product D indicates that the side chains of Val24 and Lys28 are constrained in their
movements, implying that they either are bound to the backbone or to other side chains.
A small radius of gyration Rg along with a reduced R(1,10) indicate folded conformations.
Small values of R(2,8) or R(3,8) indicate the possible formation of salt bridges between
Glu22 and Lys28 or Asp23 and Lys28, respectively. Finally, the contact maps along with
the number and type of hydrogen bonds determine the nature and strength of interactions
between different amino acids.
3 Results
Distances. In Fig. 1 we show results for R(2,8), R(3,8), R(4,8), and Rg as a function
of time. As expected, these quantities fluctuate, but they also show “events” that last
extended periods of time in which their values are substantially reduced and their fluctuations
are uncharacteristically small. R(1,10) did not exhibit “events” in any of the trajectories,
indicating that the termini are flexible (results not shown). The graph of S as a function
of time has a close functional resemblance to R(4,8) (results not shown). This functional
resemblance arises because whenever Val24 and Lys28 are in close proximity (R(4,8)< 6.5A˚),
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S is reduced from about 575A˚2 (separated and accessible to solvent) to 475A˚2.
We define “events” in Fig. 1 by: (i) R∗(4,8), in which R(4,8) < 6.5A˚ (Val24–Lys28 loop);
(ii) R∗(2,8) or R∗(3,8), in which R(2,8) or R(3,8) < 4.2A˚ (salt bridges); (iii) S∗, in which
S < 525A˚2 (Val24 and Lys28 side chain packing); and (iv) R∗g, in which Rg < 6.5A˚ (peptide
packing). We classify (i) and (iii) as hydrophobic events and (ii) as electrostatic events with
the formation of salt bridges (SB).
Events within a trajectory occur at different times and time intervals (Fig. 1). By adding
up the duration in time of these events, we obtain the total event time per trajectory (Ta-
ble 1). Values in Table 1 are reported in nanoseconds rather than as percentages because
the total simulation times are too short to obtain statistically significant percentage results.
From these data, we see that S∗ and R∗(4,8) (hydrophobic events) total times in each tra-
jectory are comparable. We also see that hydrophobic events last for much longer periods of
time than SB (R∗(2,8) and R∗(3,8)) events.
We next determine the amount of temporal overlap between pairs of events (Table 2),
helpful for establishing correlations between events. We define the percentage of overlap
for event X between two events X and Y as the time that X and Y overlap divided by
the total duration of event X , multiplied by 100. In Table 2, we divide each overlap into
two subcolumns, one for each of the events. In the first overlap column (S∗
⋂
R∗(4,8)), we
observe that in all trajectories the S∗ and R∗(4,8) events are correlated (high % of over-
lap), indicating that proximity of Val24 and Lys28 is linked to an energetically favorable
hydrophobic interaction. In the next column, the values for the overlap between the R∗(4,8)
and the SB events (R∗(2,8) and R∗(3,8) taken together) demonstrate that, except for trajec-
tories [P2] and [DU], the SB events mostly occur conditional on an existing R∗(4,8) event.
Trajectory [P2] does not allow for this overlap because of its different secondary structure
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and HB contacts (Supporting Information). In trajectory [DU] the lack of a negative charge
in the Gln22 that effectively eliminates all R∗(2,8) events might be key to the lack of R∗(4,8)
and SB overlaps. Thus, the prominent overlaps of SB with R∗(4,8) suggest that interactions
between amino acids in positions 22, 23, and 28 in the wild type may be intermediary (or
necessary) for extended R∗(4,8) events to exist.
Next, examining R∗(4,8)
⋂
R∗g we observe that for most trajectories there is a high
degree of correlation between the R∗(4,8) and R∗g events, indicating that the decapeptide has
a smaller effective size whenever Val24 and Lys28 are in close proximity. Finally, in the last
column (R∗(2,8)
⋂
R∗(3,8)) we see that the formation of the R∗(2,8) and R∗(3,8) salt bridges
is mutually exclusive (except in trajectory [RCS]). This result indicates that while Glu22
(Asp23) interacts with Lys28, Asp23 (Glu22) interacts with other amino acids or water.
In contrast, in trajectory [RCS] the large overlap between the two SB events suggests that
the ions in the solvent facilitate simultaneous formation of both SBs possibly by disrupting
properties of the water molecules surrounding the decapeptide.
Secondary Structure and Packing of Val24 and Lys28. In Fig. 2 we show the time
evolution of the secondary structure propensity of each amino acid for all the trajectories.
As with other structural determinants, there is a high degree of correlation between these
secondary structures and other events. Typically, R∗(4,8) events are correlated with increased
turn propensities that span at least the Gly25–Lys28 region (Fig.4, Supporting Information).
In Fig. 2 [P1], the pi-helix correlates with lowered values of all of the R(2,8), R(3,8), and
R(4,8) distances as well as with a very compact conformation with the lowest Rg (from Fig. 1).
We observe a similar behavior in trajectory [P2] during the helix formation in the later part
of the trajectory (75 to 80 ns). The helices in [P1] and [P2] are both formed under a pre-
existing R∗(4,8) event (compare R(4,8) from Fig. 1 with Fig. 2). We note that the prominent
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helices in [P1] and [P2] both occur in the reduced density water environments whereas in
the trajectories with normal density water there is no observable helix. In trajectory [DU],
the row corresponding to Gly25 (label “25” on the y-axis) is less populated (turn) than
the others, suggesting two turn regions separated at Gly25 (see Fig. 4 [DU], Supporting
Information, for trajectory averages).
We calculate the normalized scalar product D between the vectors formed by the side
chains of Val24 and Lys28. By comparing results on D (Fig. 5, Supporting Information) with
Fig. 1, we observe a persistence of the relative orientation of the side chains of Val24 and
Lys28 during R∗(4,8) events. These rather stable values for D indicate that during R∗(4,8)
events the side chains of Val24 and Lys28 are constrained in their relative orientation by being
bound to atoms in the monomer, increasing packing and possibly providing stability to the
hydrophobic interaction. Trajectory [DU], however, does not show the same persistence in
D values, suggesting that the lack of R∗(4,8) and R∗(2,8) events permit an unconstrained
motion of the Val24 and Lys28 side chains.
Hydrogen Bonds. An examination of the number of HBs within the decapeptide as
a function of time (Fig. 6 (upper), Supporting Information) reveals that only a handful of
short-lived HBs are active during events. In SB events, there is one HB formed between one
of the Glu22(Oǫ) (or Asp23(Oδ)) and one of the Lys28(Hζ). An exception is trajectory [RCS],
in which the two SBs are present at the same time. The hydrophobic events (R∗(4,8) and
S∗), on the other hand, are not characterized by unique HBs, but consist instead of different
HBs. In Fig. 3, we show contact maps where the strength of contacts is proportional to
the number of HBs between two amino acids. In most trajectories, Lys28 is the most active
amino acid in HB formation. In trajectory [RCS], the strongest contacts are the salt bridges
between Glu22, Asp23, and Lys28.
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By analyzing the frequency of formation of individual HBs during hydrophobic events
(Table 4, Supporting Information), we determine that the highest percentage of HBs is
formed between atoms belonging to the backbone. The most prevalent backbone HBs are
Lys28(O)-Gly25(H) and Asp23(O)-Lys28(H), and in trajectory [RC] the longest hydrophobic
event that is stabilized by the Lys28(O)-Gly25(H) also shows the tightest (smallest) loop
formation. The NH+3 group of Lys28 also participate in SB formation (Table 4, Supporting
Information) which is consistent with experimental results indicating that Lys28 in wild
type Aβ21−30 is protected from hydrogen exchange [32]. These results suggest that although
transient backbone HBs may help stabilize an already existing loop, loop formation and
long-term stability might lie in the hydrophobic interactions of Val24 and Lys28 rather than
on specific HBs. On the other hand, loop formation in trajectory [RCS] is not only driven by
hydrophobic interactions but, to a large extent, by SB interactions, suggested by the large
number of SBs in comparison to backbone HBs (Table 4, Supporting Information).
4 Discussion
In this work, we present a series of all-atom MD simulations of a decapeptide folding nucleus
of Aβ monomer (Aβ21−30) in explicit water and in water with addition of salt ions. We also
present all-atom MD simulations of the Dutch [Gln22]Aβ21−30 peptide. Our results indicate
that for all five trajectories studied (four for wild type and one for Dutch), hydrophobic
events, characterized by packing of the isopropyl group of Val24 and the butyl group of Lys28,
predominate over electrostatic events (SB between Glu22 and Lys28 or between Asp23 and
Lys28).
The hydrophobic events are highly correlated with a smaller value for the radius of
12
gyration Rg, and they last longer than SB events (Tables 1 and 2). In wild type Aβ21−30 in
normal density water, results on the distance between termini and lifetimes of backbone HBs
indicate the formation of a semi-rigid loop in the Val24–Lys28 region with highly flexible
termini, in close agreement with DMD studies [34] and consistent with NMR experiments of
Aβ21−30 [32].
In wild type Aβ21−30 in reduced density water, the Val24–Lys28 region also forms a
loop that during periods of time may belong to a larger helical structure (mostly pi- and
α-helices). The formation of a helix in our [P1] and [P2] trajectories is not surprising in
light of prior studies of Aβ and other proteins that form helices when the density of water
is effectively reduced by other solvated components [12–15, 45]. The formation of helices
in reduced density water is consistent with the possibility that hydrophobic assembly in
proteins is facilitated by removal of water molecules (“vaporization”) from regions between
hydrophobic amino acids [46]. Future work in this area will have relevance for understanding
how Aβ folding is affected by different intra- and extracellular milieus, including endoplasmic
and plasma cell membranes, endosomal/lysosomal compartments, cytoplasm, plasma, and
cerebrospinal fluid.
Although in our trajectories with pure normal water the Glu22-Lys28 and Asp23-Lys28
salt bridges are transient in time, they could be precursors to the salt bridges proposed in
recent molecular dynamics simulations [47] and modeling based on NMR data [48], where
it is suggested that the turn or bend in Aβ fibrils is stabilized by a salt bridge involving
Asp23-Lys28. In Lazo et al. [32], however, the R(2,8) and R(3,8) distances (larger than
9A˚) seem to rule out the existence of the SBs seen here. This finding can be reconciled by
considering that NMR experiments measure averages of these distances and by differences in
time scales, since the simulations here are done in the nanosecond time scale whereas NMR
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experiments are performed in the microsecond to millisecond time scales.
In wild type Aβ21−30 in normal water with solvated salt ions [RCS], we observe the
longest “waiting time” for a hydrophobic event which can be attributed to the well-known
salting-in effect in which a cloud of ions increases solubility of a protein by lowering its
electrostatic free energy [49]. In this same trajectory, the coexistence of the Glu22-Lys28
and Asp23-Lys28 SBs during the R∗(4,8) event might be a consequence of a disruption of the
HB network of the water by the solvated ions. In this scenario, ions locally reorient water
molecules, changing the HB interactions between water and Glu22 and Asp23, enhancing
the simultaneous formation of these salt bridges.
In the [DU] trajectory, the lack of hydrophobic and SB events, and the unconstrained
motion of the Val24 and Lys28 side chains, indicate a more flexible structure than the wild
type, in agreement with [50]. Taken as a whole, results on the [DU] trajectory suggest that
the Dutch mutation alters the folding pathway of the peptide. According to a postulate of
Lazo et al. [32], partial unfolding of the Ala21–Ala30 region of Aβ should occur prior to fibril
formation. If this is so, then our observation of the inability of the [DU] trajectory to form
a stable Val24-Lys28 loop might explain the higher propensity of the Dutch peptide to form
protofibrils and fibrils.
5 Conclusions
Our results show that hydrophobic interactions play a crucial role in the Aβ21−30 folding
dynamics, assisted by the formation of salt bridges between the charged amino acids. By
performing secondary structure and hydrogen bond analysis, we find that there is no reg-
ular secondary structure or permanent hydrogen bonding, suggesting that folding involves
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formation of a loop stabilized by the packing of the side chains of Val24 and Lys28. We also
show that by reducing the density of water we may induce formation of a pi-helix. Interest-
ingly, we find that in normal density water, if the solvent contains desolvated ions, the salt
bridges play a prominent role in the stabilization of the Val24–Lys28 loop. Finally, we find
that for the Dutch [Gln22]Aβ21−30 decapeptide in water, elimination of charge at position 22
disrupts the natural tendency of the monomer to form a long-lived Val24–Lys28 loop. This
substitution likely alters the Aβ folding pathway, leading to the formation of alternative turn
structures, including those stabilized solely by an Asp23–Lys28 salt bridge.
Acknowledgments
Financial support was provided by National Institutes of Health grants AG23661, NS38328,
AG18921, and NS44147; and the Bechtel Foundation.
15
References
[1] Pike, C. J, Walencewicz, A. J, Glabe, C. G, & Cotman, C. W. (1991) Brain Res. 563,
311–314.
[2] Hardy, J & Allsop, D. (1991) Trends Pharmacol. Sci. 12, 383–388.
[3] Walsh, D. M, Lomakin, A, Benedek, G. B, Condron, M. M, & Teplow, D. B. (1997) J.
Biol. Chem. 272, 22364–22372.
[4] Harper, J. D, Wong, S. S, Lieber, C. M, & Lansbury, P. T. (1997) Chem. Biol. 4,
119–125.
[5] Lambert, M. P, Barlow, A. K, Chromy, B. A, Edwards, C, Freed, R, Liosatos, M,
Morgan, T. E, Rozovsky, I, Trommer, B, Viola, K. L, Wals, P, Zhang, C, Finch, C. E,
Krafft, G. A, & Klein, W. L. (1998) Proc. Natl. Acad. Sci. USA 95, 6448–6453.
[6] Klein, W. L, Krafft, G. A, & Finch, C. E. (2001) Trends Neurosci. 24, 219–224.
[7] Yong, W, Lomakin, A, Kirkitadze, M. D, Teplow, D. B, Chen, S. H, & Benedek, G. B.
(2002) Proc. Natl. Acad. Sci. USA 99, 150–154.
[8] Walsh, D. M, Klyubin, I, Fadeeva, J. V, Cullen, W. K, Anwyl, R, Wolfe, M. S, Rowan,
M. J, & Selkoe, D. J. (2002) Nature 416, 535–539.
[9] Kirkitadze, M. D, Bitan, G, & Teplow, D. B. (2002) J. Neurosci. Res. 69, 567–577.
[10] Klein, W. L, Stine Jr., W. B, & Teplow, D. B. (2004) Neurobiol. Aging 25, 569–580.
[11] Barrow, C. J, Yasuda, A, Kenny, P. T. M, & Zagorski, M. (1992) J. Mol. Biol. 225,
1075–1093.
16
[12] Sticht, H, Bayer, P, Willbold, D, Dames, S, Hilbich, C, Beyreuther, K, Frank, R. W, &
Rosch, P. (1995) Eur. J. Biochem. 233, 293–298.
[13] Coles, M, Bicknell, W, Watson, A. A, Fairlie, D. P, & Craik, D. J. (1998) Biochemistry
37, 11064–11077.
[14] Shao, H. Y, Jao, S. C, Ma, K, & Zagorski, M. G. (1999) J. Mol. Biol. 285, 755–773.
[15] Crescenzi, O, Tomaselli, S, Guerrini, R, Salvadori, S, D’Ursi, A. M, Temussi, P. A, &
Picone, D. (2002) Eur. J. Biochem. 269, 5642–5648.
[16] Zhang, S, Iwata, K, Lachenmann, M. J, Peng, J. W, Li, S, Stimson, E. R, Lu, Y, Felix,
A. M, Maggio, J. E, & Lee, J. P. (2000) J. Struct. Biol. 130, 130–141.
[17] Gursky, O & Aleshkov, S. (2000) BBA - Protein Struct. M. 1476, 93–102.
[18] Lee, J. P, Stimson, E. R, Ghilardi, J. R, Mantyh, P. W, Lu, Y. A, Felix, A. M, Llanos,
W, Behbin, A, Cummings, M, Vancriekinge, M, Timms, W, & Maggio, J. E. (1995)
Biochemistry 34, 5191–5200.
[19] Narayanan, S & Reif, B. (2005) Biochemistry 44, 1444–1452.
[20] Klimov, D. K, Straub, J. E, & Thirumalai, D. (2004) Proc. Natl. Acad. Sci. USA 101,
14760–14765.
[21] Bitan, G, Kirkitadze, M. D, Lomakin, A, Vollers, S. S, Benedek, G. B, & Teplow, D. B.
(2003) Proc. Natl. Acad. Sci. USA 100, 330–335.
[22] Bitan, G, Vollers, S. S, & Teplow, D. B. (2003) J. Biol. Chem. 278, 34882–34889.
[23] Bitan, G, Tarus, B, Vollers, S. S, Lashuel, H. A, Condron, M. M, Straub, J. E, &
Teplow, D. B. (2003) J. Am. Chem. Soc. 125, 15359–15365.
17
[24] Urbanc, B, Cruz, L, Ding, F, Sammond, D, Khare, S, Buldyrev, S. V, Stanley, H. E, &
Dokholyan, N. V. (2004) Biophys. J. 87, 2310–2321.
[25] Urbanc, B, Cruz, L, Yun, S, Ding, F, Buldyrev, S. V, Bitan, G, Teplow, D. B, & Stanley,
H. E. (2004) Proc. Natl. Acad. Sci. USA 101, 17345–17350.
[26] Smith, S. W, Hall, C. K, & Freeman, B. D. (1997) J. Comput. Phys. 134, 16–30.
[27] Dokholyan, N. V, Buldyrev, S. V, Stanley, H. E, & Shakhnovich, E. I. (1998) Folding
and Design 3, 577–587.
[28] Dokholyan, N. V, Buldyrev, S. V, Stanley, H. E, & Shakhnovich, E. I. (2000) J. Mol.
Biol. 296, 1183–1188.
[29] Smith, A. V & Hall, C. K. (2001) Proteins Struct. Funct. 44, 344–360.
[30] Xu, Y, Shen, J, Luo, X, Zhu, W, Chen, K, Ma, J, & Jiang, H. (2005) Proc. Natl. Acad.
Sci. USA 102, 5403–5407.
[31] Massi, F & Straub, J. E. (2003) J Comput Chem 24, 143–153.
[32] Lazo, N. D, Grant, M. A, Condron, M. C, Rigby, A. C, & Teplow, D. B. (2005) Prot.
Sci. 14, 1581–1596.
[33] Fersht, A. (1999) Structure and Mechanism in Protein Science: a Guide to Enzyme
Catalysis and Protein Folding. (W. H. Freeman and Co., New York).
[34] Borreguero, J. M, Urbanc, B, Lazo, N, Buldyrev, S. V, Teplow, D. B, & Stanley, H. E.
(2005) Proc. Natl. Acad. Sci. USA 102, 6015–6020.
[35] Miravalle, L, Tokuda, T, Chiarle, R, Giaccone, G, Bugiani, O, Tagliavini, F, Frangione,
B, & Ghiso, J. (2000) J. Biol. Chem. 275, 27110–27116.
18
[36] MacKerell, J. A. D, Bashford, D, Bellott, M, L., D. J. R, Evanseck, J. D, Field, M. J,
Fischer, S, Gao, J, Guo, H, Ha, S, Joseph McCarthy, D, Kuchnir, L, Kuczera, K, Lau,
F. T. K, Mattos, C, Michnick, S, Ngo, T, Nguyen, D. T, Prodhom, B, Reiher, III, W. E,
Roux, B, Schlenkrich, M, Smith, J. C, Stote, R, Straub, J, Watanabe, M, Wiorkiewicz
Kuczera, J, Yin, D, & Karplus, M. (1998) J. Phys. Chem. B 102, 3586–3616.
[37] Kale´, L, Skeel, R, Bhandarkar, M, Brunner, R, Gursoy, A, Krawetz, N, Phillips, J,
Shinozaki, A, Varadarajan, K. , & K., S. (1999) J. Comp. Phys. 151, 283–312.
[38] Jorgensen, W. L, Chandrasekhar, J, Madura, J. D, Impey, R. W, & Klein, M. L. (1982)
J. Chem. Phys. 79, 926–935.
[39] Levy, E, Carman, M. D, Fernandez Madrid, I. J, Power, M. D, Lieberburg, I, Van
Duinen, S. G, Bots, G. T. A. M, Luyendijk, W, & Frangione, B. (1990) Science 248,
1124–1126.
[40] Humphrey, W, Dalke, A, & Schulten, K. (1996) J. Mol. Graphics 14, 33–38.
[41] Darden, T. A, York, D. M, & Pedersen, L. G. (1993) J. Chem. Phys. 98, 10089–10092.
[42] Sanner, M. F, Olson, A. J, & Spehner, J. (1996) Biopolymers 38, 305–320.
[43] Frishman, D & Argos, P. (1995) Proteins Struct. Funct. 23, 566–579.
[44] Marqusee, S & Baldwin, R. L. (1987) Proc. Natl. Acad.Sci. USA 84, 8898–8902.
[45] Fezoui, Y & Teplow, D. B. (2002) J. Biol. Chem. 277, 36948–36954.
[46] Chandler, D. (2002) Nature 417, 491–491.
[47] Ma, B. Y & Nussinov, R. (2002) Proc. Natl. Acad. Sci. USA 99, 14126–14131.
19
[48] Petkova, A. T, Ishii, Y, Balbach, J. J, Antzutkin, O. N, Leapman, R. D, Delaglio, F, &
Tycko, R. (2002) Proc. Natl. Acad. Sci. USA 99, 16742–16747.
[49] Creighton, T. (1993) Proteins: Structures and Molecular Properties, Second Edition.
(W. H. Freeman and Co., New York).
[50] Massi, F & Straub, J. E. (2001) Biophys. J. 81, 697–709.
20
Figure Captions.
Figure 1. Distances between Cα atoms of Val24 and Lys28 (R(4,8)), charged atoms of
Glu22-Lys28 (R(2,8), black), Asp23-Lys28 (R(3,8), gray), and radius of gyration Rg as a
function of time for each trajectory. All of the distances are measured in A˚.
Figure 2. Secondary structure of each amino acid as a function of time for each of the
trajectories. The amino acid numbering is sequential from 21 (Ala21) to 30 (Ala30). The
colors in the graphs correspond to: turn (green), bridge (tan), α-helix (pink), pi-helix (red),
and coil (white - none of the above).
Figure 3. Hydrogen bond contact maps for each of the trajectories. The level of darkness
of each contact is proportional to the number of HBs between two amino acids (from
Table 4, Supporting Information). The grayscale values for each contact map are relative to
the maximum and minimum number of HBs from each trajectory. The strongest contacts
per trajectory are: in [RC] between the Gly25 and Lys28; in [P1] between the Asp23 and
Lys28; in [P2] between the Val24 and Gly29; in [DU] between the Gly25 and Lys28; and in
[RCS] between the Glu22 and Lys28, and Asp23 and Lys28.
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